Primary-source record
This quarterly update restates that the pivotal Phase 3 OPERA-01 trial of palazestrant remains on track to report top-line data in Q1 2027. It also notes continued strong enrollment in the pivotal Phase 3 OPERA-02 trial of palazestrant plus ribociclib.
EX-99.1 2 olma-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Olema Oncology Reports Third Quarter 2026 Financial and Operating Results • On track to announce top-line data from the pivotal Phase 3 OPERA-01 trial in the first quarter of 2027 • Continued strong enrollment in the pivotal Phase 3 OPERA-02 trial and the Phase 1b/2 study of OP-3136 • Appointed Jason O’Byrne, MBA, as Chief Financial Officer • Ended the third quarter with $413.8 million in cash, cash equivalents, and marketable securities SAN FRANCISCO, November 10, 2026 (Globe NewsWire) – Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the third quarter ended September 30, 2026. “As we approach top-line data from our pivotal Phase 3 OPERA-01 trial in the first quarter of 2027, we remain confident in palazestrant’s potential to emerge as a differentiated endocrine therapy in second- and third-line metastatic breast cancer,” said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. “Turning to our pivotal Phase 3 OPERA-02 trial in first-line metastatic breast cancer, momentum continues to build. Enrollment is accelerating, investigator interest is strong, and patients with frontline disease continue to require better therapeutic options. We believe that pa